Tamarind seeds join the fight against dry eye

Article

Tamarind seed polysaccharide (TSP) 0.5% and 1% offers at least equivalent relief from dry eye symptoms as hyaluronic acid (HA), according to a study published online by BMC Ophthalmology in March.

Tamarind seed polysaccharide (TSP) 0.5% and 1% offers at least equivalent relief from dry eye symptoms as hyaluronic acid (HA), according to a study published online by BMC Ophthalmology in March.

Maurizio Rolando and Cristiana Valente from the University of Genoa, Italy compared the activity of TSP and HA in an open-label, randomized, single centre clinical study. Thirty subjects were randomized to receive three or more applications per day of either TSP 0.5%, TSP 1% or HA 0.2% over a 90 day period. Tolerability was assessed by visual analogue scale (VAS).

TSP 0.5% and 1% were comparable to HA in terms of tolerability, stability of the pre-corneal tear film and corneal and conjunctival staining. However, TSP was found to be more beneficial than HA in terms of addressing subjective symptoms such as trouble blinking, ocular burning and foreign body sensation.

It was concluded that TSP is at least as effective against dry eye as HA and the authors suggest that larger studies are required to further establish the efficacy and safety of the compound as a treatment for dry eye syndrome.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.